Zeiss
- Board have meet twice (september and last week) you would have to think something substantial is going on
- we can advise that with a goal of FDA approval over the next 6-9 months, Optiscan will move into commercialisation and production soon after
-Never before has revenue generation been so close and we are now close to delivering considerable financial benefits to Optiscan and its shareholders in the form of significant lifts in revenue and profit in the 2017/18 financial year.
-The collaboration project is at the point where Production Equivalent Systems will be supplied to Carl Zeiss in December 2016 for testing and validation over the coming months (these orders should increase cash position)
ViewnVivo
- has the potential to provide significant lifts in Optiscan’s revenue and profit commencing in the 2nd quarter of the 2017 calendar year and into the 2017/18 financial year and beyond.
For first time since i have held this stock i truly believe that it could be the star of the ASX in 2017
Add to My Watchlist
What is My Watchlist?
